Balicatib
Balicatib is an inhibitor of cathepsin K that displays anti-resorptive activity. Balicatib inhibits osteoclast activity, decreasing bone turnover and increasing bone mineral density and bone formation rates.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18842996
| Cas No. |
354813-19-7 |
|---|---|
| Formula |
C23H33N5O2 |
| Formula Wt. |
411.55 |
| IUPAC Name |
N-{1-[(Cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propyl-1-piperazinyl)benzamide |
| Synonym |
AAE-581 |
Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012 Jan;23(1):339-49. PMID: 21380636.
Chappard D, Libouban H, Mindeholm L, et al. The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients. Microsc Res Tech. 2010 Jul;73(7):726-32. PMID: 20025055.
